Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.
JAMA psychiatry April 2, 2025 Antonio Del Casale, Sara Spirito, Jan Francesco Arena et al. 17 citations
Among adults with treatment-resistant depression, combining esketamine with an SNRI was associated with lower all-cause mortality (5.3% vs 9.1%), fewer hospitalizations (0.1% vs 0.2%), and fewer depression relapses (14.8% vs 21.2%) compared to combining esketamine with an SSRI. However, the esketamine plus SSRI group had a slightly lower incidence of suicide attempts (0.3% vs 0.5%). Overall rates of these outcomes were low in both groups. The findings come from a large real-world analysis of electronic medical records from over 90 health care centers across 20 countries.